4 ms·
> if you sort of detach yourself and look from a business perspective and value-based pricing, Epipen competes with the ER, and $600 is a bargain vs an ER visit
by r00fus 10y ago
> if you sort of detach yourself and look from a business perspective and value-based pricing, Epipen competes with the ER, and $600 is a bargain vs an ER visit.
This is exploitation of inelastic demand (death is a pretty high priced alternative to $600), and it's pretty clear that's exactly what government regulations and market controls are supposed to protect against.
- chillacy 10y agoYes, that is the conclusion that he reached: that the government should just nationalize generics for public benefit. That's sort of the extreme version of mandated pricing. Someone else in the comment section shared another perspective which reaches the opposite conclusion: that these regulations have created the problems in the first place, and the government should not touch this sector at all: http://slatestarcodex.com/2016/08/29/reverse-voxsplaining-drugs-vs-chairs/ http://slatestarcodex.com/2016/08/29/reverse-voxsplaining-dr...